IL10RA Modulates Crizotinib Sensitivity in NPM1-ALK-positive Anaplastic Large Cell Lymphoma

Anaplastic Large Cell Lymphoma (ALCL) is a T-cell malignancy predominantly driven by a hyperactive Anaplastic Lymphoma Kinase (ALK) fusion protein. ALK inhibitors such as crizotinib provide alternatives to standard chemotherapy with reduced toxicity and side effects. Children with lymphomas driven b...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2020-06, Vol.13 (1)
Main Authors: Prokoph, Nina, Probst, Nicola Anna, Lee, Liam Changwoo, Monahan, Jack Michael, Matthews, Jamie David, Liang, Huan-Chang, Bahnsen, Klaas, Montes-Mojarro, Ivonne A, Karaca Atabay, Elif, Sharma, Geeta Geeta, Malik, Vikas, Larose, Hugo, Forde, Sorcha Denise, Ducray, Stephen Paul, Lobello, Cosimo, Wang, Qi, Luan, Shi-Lu, Pospisilova, Sarka, Gambacorti-Passerini, Carlo B, Burke, Amos, Pervez, Shahid, Attarbaschi, Andishe, Janikova, Andrea, Pacquement, Helene, Landman-Parker, Judith, Lambilliotte, Anne, Schleiermacher, Gudrun, Klapper, Wolfram, Jauch, Ralf, Woessmann, Wilhelm, Vassal, Gilles, Kenner, Lukas, Merkel, Olaf, Mologni, Luca, Chiarle, Roberto, Brugieres, Laurence, Geoerger, Birgit, Barbieri, Isaia, Turner, Suzanne D
Format: Article
Language:English
Subjects:
Life Sciences
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anaplastic Large Cell Lymphoma (ALCL) is a T-cell malignancy predominantly driven by a hyperactive Anaplastic Lymphoma Kinase (ALK) fusion protein. ALK inhibitors such as crizotinib provide alternatives to standard chemotherapy with reduced toxicity and side effects. Children with lymphomas driven by NPM1-ALK fusion proteins achieved an objective response rate to ALK inhibition therapy of 54-90% in clinical trials. However, a subset of patients progress within the first 3 months of treatment. The mechanism for the development of ALK inhibitor resistance is unknown. Through genome-wide CRISPR activation and knockout screens in ALCL cell lines combined with RNA-seq data derived from ALK inhibitor relapsed patient tumors, we show that resistance to ALK inhibition by crizotinib in ALCL can be driven by aberrant upregulation of IL10RA. Elevated IL10RA expression rewires the STAT3 signaling pathway bypassing otherwise critical phosphorylation by NPM1-ALK. IL10RA expression does not correlate with response to standard chemotherapy in pediatric patients suggesting that combination of crizotinib with chemotherapy could prevent ALK-inhibitor resistance-specific relapse. Trials registered as NCT01979536/NCT02034981/UMIN000028075.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.2019003793